Table 1.
Demographic, clinical and laboratory features of the COVID-19 patients
| Parameter | Patients (n = 34) |
|---|---|
| Demographic data | |
| Age* | 61.7 ± 2 |
| Sex Male | 13 (38.2%) |
| Female | 21 (61.8%) |
| Clinical findings | |
| Dyspnea | 26 (76.5%) |
| Fever | 25 (73.5%) |
| Cough | 26 (76.5%) |
| Diarrhea | 23 (67.6%) |
| Headache | 7 (20.6%) |
| Myalgia | 13 (38.2%) |
| Fatigue | 18 (52.9%) |
| Anorexia | 8 (23.5%) |
| Sore throat | 11 (32.4%) |
| Severity | |
| Non-severe | 20 (59%) |
| Severe | 14 (41%) |
| Diabetic patients | 23 (67.6%) |
| FBG (70–99 mg/dl) | 222.8 ± 17 |
| −diabetic patients | 273 ± 20 |
| -non-diabetic patients | 129.5 ± 8 |
| HA1c (4–5.6%) | 6.7 ± .2 |
| CBC findings* | |
| TLC (4-11X109/L) | 11.6 ± 1 |
| Neutrophil count (2–7 ×109/L) | 10.6 ± 1 |
| Lymphocyte count (1–4.8 ×109/L) | 2 ± .4 |
| COVID-19 related tests* | |
| CRP (up to 1 mg/dl) | 63.5 ± 9 |
| Ferritin (22–322 ng/ml) | 843.4 ± 156 |
| D dimer (up to .55 mg/L) | 2.8 ± .5 |
| LDH (100–190 U/L) | 427.2 ± 34 |
| Renal functions* | |
| Urea (2.5–7.1 µmol/L) | 12.2 ± 2 |
| Creatinine (44.2–97 µmol/L) | 138.6 ± 25 |
| Liver functions* | |
| ALT (0–45 U/L) | 33.1 ± 3.4 |
| AST (0–34 U/L) | 38.5 ± 3 |
| Total protein (64–83 g/L) | 57 ± 2 |
| Albumin (34–50 g/L) | 29.5 ± 1 |
| Total bilirubin (0–34 µmol/L) | 19.9 ± 4 |
| Direct bilirubin (0–3.4 µmol/L) | 8.2 ± 2 |
| Prothrombin time (11–14 sec) | 13.4 ± .4 |
| Prothrombin concentration (70–130%) | 84.6 ± 3 |
| Blood gases* | |
| SpO2 (>95%) | 84.5 ± 2 |
| PaCO2 (35–45 mmHg) | 33.2 ± 2 |
| Respiratory rate (13–28/min) * | 32.4 ± 2 |
Data were presented as number (percentage) or *mean ± SE (normal reference ranges.
FBG fasting blood glucose, CBC complete blood count, TLC total leukocyte count, CRP C-reactive protein, LDH lactate dehydrogenase, ALT alanine aminotransferase, AST aspartate aminotransferase, SpO2 Oxygen saturation, PaCO2 partial pressure of carbon dioxide.